POS0532 DEUCRAVACITINIB, AN ORAL, ALLOSTERIC, TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT-REPORTED OUTCOMES IN A PHASE 2 TRIALMarta Mosca, Vibeke Strand, Anca Askanase et al.|Annals of the Rheumatic Diseases|2024Cited by 0